Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Raised to $52.00

Apellis Pharmaceuticals (NASDAQ:APLS) had its price objective hoisted by Robert W. Baird from $50.00 to $52.00 in a research report released on Friday,Benzinga reports. Robert W. Baird currently has an outperform rating on the stock.

A number of other equities analysts have also weighed in on APLS. Cantor Fitzgerald increased their target price on shares of Apellis Pharmaceuticals from $39.00 to $40.00 and gave the stock an “overweight” rating in a research report on Friday, August 1st. The Goldman Sachs Group lowered shares of Apellis Pharmaceuticals from a “neutral” rating to a “sell” rating and cut their target price for the stock from $26.00 to $18.00 in a research report on Friday, September 26th. HC Wainwright cut their target price on shares of Apellis Pharmaceuticals from $57.00 to $45.00 and set a “buy” rating for the company in a research report on Friday. Weiss Ratings reiterated a “sell (e+)” rating on shares of Apellis Pharmaceuticals in a research report on Wednesday, October 8th. Finally, Royal Bank Of Canada increased their target price on shares of Apellis Pharmaceuticals from $17.00 to $19.00 and gave the stock a “sector perform” rating in a research report on Friday, August 1st. Ten investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $33.50.

Apellis Pharmaceuticals Stock Performance

NASDAQ APLS opened at $21.47 on Friday. Apellis Pharmaceuticals has a 52-week low of $16.10 and a 52-week high of $35.72. The company has a 50-day simple moving average of $25.51 and a 200 day simple moving average of $21.74. The company has a debt-to-equity ratio of 2.90, a quick ratio of 3.16 and a current ratio of 3.77. The company has a market capitalization of $2.72 billion, a PE ratio of 69.26 and a beta of 0.70.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its earnings results on Thursday, October 30th. The company reported $1.67 earnings per share for the quarter, topping analysts’ consensus estimates of $1.03 by $0.64. The firm had revenue of $458.58 million during the quarter, compared to analyst estimates of $364.58 million. Apellis Pharmaceuticals had a net margin of 4.43% and a return on equity of 24.58%. The company’s quarterly revenue was up 133.0% on a year-over-year basis. During the same quarter last year, the business earned ($0.46) earnings per share. On average, research analysts predict that Apellis Pharmaceuticals will post -1.7 EPS for the current year.

Insider Activity

In other news, Director A. Sinclair Dunlop sold 31,092 shares of the firm’s stock in a transaction that occurred on Friday, October 10th. The shares were sold at an average price of $23.72, for a total value of $737,502.24. Following the completion of the transaction, the director directly owned 3,837 shares in the company, valued at approximately $91,013.64. This trade represents a 89.01% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Timothy Eugene Sullivan sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 21st. The shares were sold at an average price of $28.03, for a total transaction of $280,300.00. Following the completion of the transaction, the chief financial officer owned 110,936 shares of the company’s stock, valued at $3,109,536.08. This trade represents a 8.27% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 312,921 shares of company stock valued at $8,490,866 over the last ninety days. 6.80% of the stock is owned by insiders.

Institutional Investors Weigh In On Apellis Pharmaceuticals

Hedge funds have recently bought and sold shares of the stock. Woodline Partners LP lifted its position in Apellis Pharmaceuticals by 15.5% during the first quarter. Woodline Partners LP now owns 218,850 shares of the company’s stock valued at $4,786,000 after purchasing an additional 29,373 shares during the last quarter. Wealth Enhancement Advisory Services LLC raised its stake in shares of Apellis Pharmaceuticals by 43.5% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 100,666 shares of the company’s stock worth $1,838,000 after acquiring an additional 30,507 shares in the last quarter. Cerity Partners LLC raised its stake in shares of Apellis Pharmaceuticals by 16.7% during the first quarter. Cerity Partners LLC now owns 54,444 shares of the company’s stock worth $1,191,000 after acquiring an additional 7,777 shares in the last quarter. Bayforest Capital Ltd raised its stake in shares of Apellis Pharmaceuticals by 431.9% during the first quarter. Bayforest Capital Ltd now owns 52,338 shares of the company’s stock worth $1,145,000 after acquiring an additional 42,499 shares in the last quarter. Finally, Pallas Capital Advisors LLC raised its stake in shares of Apellis Pharmaceuticals by 29.0% during the second quarter. Pallas Capital Advisors LLC now owns 54,849 shares of the company’s stock worth $949,000 after acquiring an additional 12,315 shares in the last quarter. 96.29% of the stock is currently owned by institutional investors.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).